Search

Your selection

None

Filter by content type

Filter by content year

News

Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

March 12, 2026 - … net   2,826     3,557     Goodwill   4,508     4,508       Total assets $ 186,079   $ 166,389               Liabilities … related to sale of future royalties   4,060     5,758     Total liabilities   98,281     107,464     Stockholders’ equity   87,798     58,925       Total liabilities and stockholders’ equity $ 186,079   $ …
News

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

November 13, 2025 - …                       4,508                      4,508 Total assets $                208,988   $             166,389 …                       3,514                     5,758 Total liabilities                   182,232                   …                      26,756                     58,925 Total liabilities and stockholders’ equity $                …
News

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

News

Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

August 13, 2025 - … 3,192     3,557     Goodwill         4,508     4,508       Total assets       $ 164,085   $ 166,391                     … related to sale of future royalties   2,907     5,758     Total liabilities         131,207     107,465     Stockholders’ equity       32,878     58,926       Total liabilities and stockholders’ equity $ 164,085   $ …
News

Vaxart Announces Adjournment of Annual Meeting of Stockholders

May 21, 2025 - … because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks; … because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks; … because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks; …
News

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2025 - … of Vaxart’s common stock, which vests as to 1/4th of the total shares on the one-year anniversary of his start date, and as to 1/48th of the total shares on each month thereafter, and has a per share … of Vaxart’s common stock, which vests as to 1/4th of the total shares on the one-year anniversary of his start date, …
News

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

News

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025 - … net   3,375       3,557   Goodwill   4,508       4,508   Total assets $ 158,559     $ 166,389           Liabilities … related to sale of future royalties   3,734       5,758   Total liabilities   112,941       107,464   Stockholders’ equity   45,618       58,925   Total liabilities and stockholders’ equity $ 158,559     $ …
News

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

May 12, 2025 - … Vaxart . For example, if you own 100 shares at $1.00 each (total value $100 ) and there is a 1-for-10 reverse stock … would own 10 shares at an anticipated $10.00 each (still a total value of $100 ), excluding any potential market … Vaxart . For example, if you own 100 shares at $1.00 each (total value $100 ) and there is a 1-for-10 reverse stock …
News

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 27, 2025 - … with Vaxart . The stock options vest as to 1/4th of the total shares on the one-year anniversary of the grant date, and as to 1/48th of the total shares on each month thereafter, and have a per share … with Vaxart . The stock options vest as to 1/4th of the total shares on the one-year anniversary of the grant date, …
Scroll to Top